Hydroxychloroquine and Cardiovascular Events in Patients with Rheumatoid Arthritis.

INTRODUCTION: Cardiovascular disease (CVD) is the leading cause of mortality in patients with rheumatoid arthritis (RA). Some studies have reported a decrease in CVD in patients with RA using hydroxychloroquine (HCQ). Most of these have had fewer participants and have analyzed only composite outcomes. We aimed to identify the association between the use of HCQ in patients with RA and the incidence of major adverse cardiac events (MACEs), cerebral infarction, and AMI.
METHODS: This was a retrospective observational study using the TriNetX Diamond Network. Propensity score matching (PSM) was used to equilibrate the cohorts. The dependent variables in our study were MACE, cerebral infarction, and AMI.
RESULTS: A total of 2,261,643 patients with RA were identified. Approximately 6% had been prescribed HCQ. Of those prescribed HCQ, 80% (112,743) were females, while of those not prescribed HCQ, 72.5% (1,536,937) were females. HCQ was associated with lower rates of MACE (HR 0.827, 95%CI 0.8,0.86), cerebral infarction (HR 0.824, 95% CI 0.78,0.87), and AMI (HR 0.9, 95% CI 0.85,0.96). These associations were not seen in patients taking biologics. HCQ was associated with lower MACE in all other subgroups.
CONCLUSION: In conclusion, HCQ was slightly beneficial in decreasing MACE and cerebral infarction in patients with RA. These associations were significantly lower in patients taking methotrexate or biologics. Although there was a significant decrease in the risk of AMI in all patients with RA, these results were not replicated in subgroup analyses, and there was an apparent increased risk of AMI with the use of HCQ in patients using biologics.

Introduction

Cardiovascular disease (CVD) is a leading cause of mortality in patients with rheumatoid arthritis (RA) [1, 2]. The relative risk of myocardial infarction in patients with RA is 2.0 (95% CI 1.232–3.29) [2]. Although some studies have shown an increased prevalence of CVD risk factors in patients with RA, the higher incidence of cardiovascular events is not fully explained by these risk factors alone [3]. CVD mortality in patients with RA is approximately 50% higher than in the general population [1], and inflammation has been postulated as the main driver for this increased risk [4, 5]. This is supported by high levels of cytokines in their plasma [6] and the decrease in CVD seen with anti-TNF and methotrexate [7-9]. RA has been associated with peripheral insulin resistance [10], dyslipidemia [11], endothelial dysfunction [12, 13], increased levels of fibrinogen, Von Willebrand factor, d-dimer, tissue plasminogen antigen [14], and platelet reactivity [15, 16], all of which can promote the development of CVD.

Hydroxychloroquine (HCQ) has been associated with decreased cardiovascular death in patients with RA, likely because of its beneficial effects on lipids, glucose, coagulation, inflammation, and endothelial function [17, 18]. Most studies before ours have had a smaller number of participants and have analyzed only composite outcomes (AMI, stroke, TIA, PAD) [17, 18]. This study aimed to determine the association between the use of HCQ in patients with RA and the odds of presenting AMI, CAD, and cerebral infarction by analyzing data from a large database of patients in the US healthcare system.

Materials and Methods

Data Source

We used the TriNetX Diamond Network, which provided access to third-party data from electronic medical records of community-based primary and specialty care, medical claims from claims clearinghouses (including inpatient, outpatient, specialty, PCP, and ancillary care settings), and pharmacy claims. This data is harmonized and curated by TriNetX every 3 months. Overall, the dataset represents 92 sites, 212 million patients, and 99% of U.S. health plans since 2014.

The TriNetX platform classifies diagnoses in ICD-10 codes. For health care organizations that provide data in ICD-9, the TriNetX platform transforms that data into ICD-10. More information regarding this dataset and the TriNeTx platform can be found at www.trinetx.com.

Study Design and Population

We performed a retrospective observational cohort study using the TriNetX Diamond Network, which provided access to third-party longitudinal data from 92 sites, 212 million patients, and 99% of US health plans. The data for this study was collected and analyzed in August 2022.

TriNetX, LLC complies with the Health Insurance Portability and Accountability Act (HIPAA) and any additional data privacy regulations applicable to the contributing healthcare organizations. TriNetX is certified to the ISO 27001:2013 standard and maintains an Information Security Management System to protect the healthcare data it has access to and meet the HIPAA Security Rule requirements. Any data displayed on the TriNetX Platform in aggregate form, or any patient-level data provided in a dataset generated by the TriNetX Platform, only contains de-identified data as per the de-identification standard defined in Section §164.514(a) of the HIPAA Privacy Rule. Because this study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, this study was exempted from Institutional Review Board approval.

Inclusion and Exclusion Criteria

We included patients ≥ 18 years old with RA diagnosis defined as International Classification of Diseases, tenth Revision, Clinical Modification (ICD-10-CM), codes M05 (Rheumatoid Arthritis with Rheumatoid Factor) and M06 (other Rheumatoid Arthritis).

Our exposed cohort was defined as patients with a first prescription of HCQ recorded between January 1, 2016 and January 1, 2022, after any documented RA. We excluded all patients < 18 years old and any patients with a prescription of HCQ on or before December 31, 2015. The un-exposed cohort was defined by patients with a diagnosis of RA who did not have any recorded prescription of HCQ.

Four subgroups were analyzed: females, males, patients taking methotrexate (defined as the first instance of methotrexate prescription after an RA diagnosis that had not been on methotrexate on or before December 31, 2015), patients taking biologics (defined as the first instance of biologics prescription after an RA diagnosis that had not been on biologics on or before December 31, 2015). The medications considered as biologics were golimumab, anakinra, abatacept, tocilizumab, adalimumab, upadacitinib, etanercept, baricitinib, sarilumab, infliximab, infliximab, certolizumab pegol, and tofacitinib.

Dependent Variables

The dependent variables in our study were MACE (ICD-10 codes: I21, I22, I23, I24, I63, I65, I66), cerebral infarction (ICD-10 I63), and AMI (ICD-10 I21).

Data Collection

The TriNetX Diamond network was queried from January 2016 to January 2022. Outcomes were analyzed from 1 month to 5 years after the index event.

Statistical Analysis

All statistical analysis was performed using the TriNetX online platform. Baseline characteristics were compared using chi-square for categorical data and mean with standard deviation for continuous data.

Propensity score matching (PSM) was used to adjust for differences between cohorts. The TriNetX platform calculates propensity scores using logistic regression and then uses greedy nearest-neighbor matching algorithm to obtain matched cohorts with a caliper width of 0.1 pooled standard deviations. The covariates used in 1:1 PSM were age, sex, race, hypertensive diseases (ICD-10 I10 to I16), neoplasms (ICD-10 C00 to D49), diabetes mellitus (ICD-10 E08 to E13), atherosclerotic heart disease of native coronary artery (ICD-10 I25.1), chronic kidney disease (CKD) (ICD-10 N18), cerebral infarction (ICD-10 I63), acute myocardial infarction (ICD-10 I21), ischemic cardiomyopathy (ICD-10 I25.5), cardiovascular medications (including antilipemic agents, diuretics, beta-blockers, ace inhibitors, calcium channel blockers, angiotensin ii inhibitor, antiarrhythmics, antianginals, alpha-blockers), and methotrexate use.

After PSM, hazard ratios (HRs) with 95% confidence intervals (CIs) and Kaplan Meier survival analysis were calculated. The TriNetX platform calculates HR and proportionality with R’s Survival package v3.2–3 and validates the numbers by comparing them with SAS version 9.4. For each analysis, patients with a history of the event were excluded. Statistical significance of the difference between cohorts in the Kaplan–Meier analysis was assessed with the log-rank test. A P value of < 0.05 was considered statistically significant.

Results

All results are summarized in Figs. 1 and 2 and Tables 1 and 2.

Fig. 1

Forest plot representing outcomes/HR with 95%

Fig. 2

Kaplan Meier analysis of all patients with RA

Table 1

Cohort characteristics after propensity score matching in patients with RA with and without HCQ

Results of PSM
	Hydroxychloroquine prescription				SD
	Yes		No
Total number of patients	140,857		140,857
Age mean (SD)	60.4 (14.6)		60.4 (14.6)
	N	Percentage	N	Percentage
Females	112,743	80.04%	112,783	80.07%	0.00071067
Males	28,084	19.94%	28,029	19.90%	0.00097767
Unknown race	91,277	64.80%	91,201	64.75%	0.00112955
White	43,071	30.58%	43,289	30.73%	0.00335675
Black or African American	5892	4.18%	5764	4.09%	0.00456287
Asian	617	0.44%	603	0.43%	0.00151362
Hypertensive diseases	79,834	56.68%	79,778	56.64%	0.00080228
Neoplasms	49,780	35.34%	49,722	35.30%	0.0008615
Diabetes mellitus	33,794	23.99%	33,646	23.89%	0.00246234
Atherosclerotic heart disease of native coronary artery	18,824	13.36%	18,655	13.24%	0.0035328
Chronic kidney disease (CKD)	14,730	10.46%	14,511	10.30%	0.00509767
Cerebral infarction	4366	3.10%	4212	2.99%	0.00636312
Acute myocardial infarction	3220	2.29%	2866	2.04%	0.01728709
Ischemic cardiomyopathy	1210	0.86%	1032	0.73%	0.01422244
Cardiovascular medications	88,984	63.17%	89,163	63.30%	0.00263562
Methotrexate	36,388	25.83%	36,273	25.75%	0.00186616

SD standard difference, N number.

Table 2

Outcomes

	On HCQ		Not on HCQ
	N	Outcome	N	Outcome	HR (95% CI)
All patients with RA
MACE	127,139	4844	126,456	7470	0.827(0.798–0.858)
Cerebral Infarction	136,115	2040	135,815	3188	0.824(0.779–0.872)
AMI	137,280	1838	137,323	2701	0.9(0.848–0.956)
Patients taking MTX
MACE	27,154	848	27,398	1084	0.864(0.789–0.945)
Cerebral Infarction	28,865	353	28,965	449	0.869(0.755–0.999)
AMI	29,089	305	29,221	368	0.919(0.789–1.069)
Patients taking biologics
MACE	13,805	413	13,991	468	1.099(0.962–1.256)
Cerebral Infarction	14,642	168	14,744	189	1.095(0.889–1.35)
AMI	14,728	179	14,838	166	1.341(1.084–1.659)
Males
MACE	24,500	1225	24,287	1805	0.841(0.781—0.904)
Cerebral Infarction	26,980	456	26,972	713	0.812(0.721—0.914)
AMI	26,930	542	26,914	736	0.937(0.838—1.048)
Females
MACE	102,611	3619	102,261	5652	0.826(0.792—0.862)
Cerebral Infarction	109,106	1584	108,903	2503	0.929 (0.865—0.998)
AMI	110,320	1296	110,333	1854	0.929(0.865—0.998)

MACE major adverse cardiac events, AMI acute myocardial infarction, HR hazard ratio, CI confidence interval.

Patient Characteristics

A total of 2,261,643 patients with RA were identified. Patients (6.2%) (140,857) had been prescribed HCQ. Of those prescribed HCQ, 80% (112,743) were females, while of those not prescribed HCQ, 72.5% (1,536,937) were females. The median age was 60.4 ± 14.6 and 62.6 ± 15.1 for patients that received HCQ and those who did not, respectively.

After PSM, each cohort had 140,857 patients, and all covariates were equilibrated with a SD of < 0.1. Baseline characteristics after PSM can be seen in Table 1. All the subgroups were matched with PSM with SD < 0.1 for all the covariates. The characteristics of each subgroup before and after PSM alongside propensity score density graphs can be seen in the supplementary material.

Outcomes

Major Cardiovascular Events

Among patients with RA, MACE was 17% lower in patients with HCQ (HR 0.827, 95%CI 0.8, 0.86). Similar results were seen in subgroup analysis, with 13% lower in those taking methotrexate (HR 0.864, 95%CI 0.8, 0.95), 16% in males (HR 0.841, 95% CI 0.78, 0.9), and 17% in females (HR 0.826, 95% CI 0.79, 0.86). There was no significant association in patients taking biologics (HR 1.099, 95% CI 0.96, 1.3).

Cerebral Infarction

Cerebral infarction was lower in patients using HCQ across all groups except for those on biologics (HR 1.095, 95% CI 0.89, 1.35): 18% lower in all patients with RA (HR 0.824, 95% CI 0.78, 0.87) and 16% lower in males (HR 0.812, 95% CI 0.72, 0.91). Although statistically significant, the upper CI for HR in females and patients on methotrexate was 0.99 making the interpretation of these results more difficult.

Acute Myocardial Infarction

Patients with RA receiving HCQ had 10% less AMI than those without (HR 0.9, 95% CI 0.85, 0.96). Females also had a statistically significant association with AMI (HR 0.929, 95% CI 0.865, 0.998). In patients taking biologics, they were 34% higher in the group with HCQ (HR 1.341, 95% CI 1.084, 1.659).

Discussion

HCQ was associated with lower rates of MACE and cerebral infarction across all subgroups, except for those on biologics. It is important to point out that the upper 95% CI of the HR for cerebral infarction was 0.999 in females and patients on methotrexate, making difficult the interpretation of these results. Although there was a significant association with lower AMI in all patients with RA, this was not reproduced in subgroup analysis. Patients on biologics had an increased risk of AMI with HCQ. Our work is in line with recent studies that have reported a positive association between the use of HCQ in patients with RA and CVD [17, 18] and contrasts those results from Lane et al., who performed a large retrospective study and found that long-term HCQ use was associated with increased risk of cardiovascular mortality when compared to sulfasalazine (HR 1.65 95%CI 1.12–2.44) and did not find a significant association with AMI, all-cause mortality, and stroke [19] and with the work of D’Andrea et al., who showed no difference in AMI and stroke between HCQ and methotrexate [20]. Although these results show that HCQ has similar or poorer cardiovascular outcomes compared to sulfasalazine and methotrexate, our study has the benefit of comparing the use of HCQ versus no HCQ in different subgroups of patients, including those taking other disease-modifying antirheumatic drugs (DMARDs).

There are several mechanisms by which HCQ may decrease the risk of atherosclerosis in patients with RA. Most of its action is likely due to its effects on lipids, glucose, coagulation, inflammation, and endothelial function. HCQ modulates the ATM (ataxia-telangiectasia mutated) protein kinase pathway with subsequent decreased JNK (Jun-N- terminal kinase) and LPL activity in macrophages [21]. JNK decreases adiponectin [22], and its inhibition increases insulin sensitivity [23] and decreases atherosclerosis [24, 25]. Although some experimental studies have failed to prove changes in serum cholesterol levels [21, 25], pooled data analysis from a meta-analysis showed significant changes in total cholesterol (− 13.1 mg/dL 95%CI − 20.9 to − 5.3), LDL (− 12.3 mg/dL 95%CI − 20.2 to − 4.6), triglycerides (− 12.5 mg/dL 95%CI − 28.9 to 3.9), and HDL (+ 1.6 mg/dL 95%CI − 0.96 to 4.3) [26]. Its effects on glucose control are evidenced by decreased incidence of diabetes mellitus (HR 0.59 95%CI 0.49–0.7) [26], improved insulin sensitivity in obese populations[27], and better glycemic control [28]. These are likely due to inhibition of insulin degradation by decreased leukocyte lysosomal enzymes, alpha-glucosidase, and hexosaminidase-A [29] and increased insulin receptor affinity[30] and insulin secretion [31].

HCQ inhibits platelet aggregation by acting in the arachidonic acid cascade via inhibition of lysosomal phospholipase A and C [32, 33]. On the vasculature, it stimulates the release of nitric oxide in endothelial cells inhibiting endothelial cell proliferation [34]. HCQ may decrease inflammation by lowering the release of TNF-alpha, blocking its conversion to mature protein from its precursor and diminishing the release of IL-1 and IL-6 as well as their mRNA levels [35]. The fact that the associations were weaker in patients taking other DMARDs supports the theory that CVD in patients with RA may be mediated, at least in part, by inflammation. This is supported by the CANTOS trial, where the use of canakinumab (a therapeutic monoclonal antibody targeting interleukin-1β) led to a significantly lower rate of recurrent cardiovascular events than placebo, independently of lipid levels [36]. The use of HCQ in patients taking other methotrexate was associated with lower MACE. There was no association between patients taking biologics and MACE or cerebral infarction. Interestingly, this group of patients had higher AMI with HCQ. These results are of particular importance, considering that the use of HCQ alone in patients with RA is only moderately effective and may be better used in conjunction with other DMARDs[37].

Considering the high percentage of females in our study, subgroups of females and males were analyzed. There was a slightly lower risk of MACE in both groups. There was no statistically significant association with AMI in males. In females, there was a lower risk of AMI and cerebral infarction; however, the upper limit of CI interval was close to one, making the interpretation of these results difficult. This contrasts with the work by Hung et al., who reported decreased incidence of CAD in female patients with RA on HCQ (HR 0.3, P < 0.01) but did not find a significant association in male patients [18]. This could have been due to the low number of males included after PSM. Our study has the advantage of a larger population (approximately 27,000 versus 49 males), which may have allowed us to find more differences.

It is important to remember that HCQ can have significant side effects, mainly arrhythmias and heart failure [38], and its safety profile has recently been put into consideration given the widespread use of the medication at the early times of the COVID-19 pandemic [39].

In conclusion, HCQ was slightly beneficial in decreasing MACE and cerebral infarction in patients with RA. These associations were significantly lower in patients taking methotrexate or biologics. Although there was a significant decrease in the risk of AMI in all patients with RA, these results were not replicated in subgroup analyses, and there was an apparent increased risk of AMI with the use of HCQ in patients using biologics. Considering that the safety profile of the use of HCQ in patients with RA has not been completely elucidated, more studies and, if possible, randomized controlled trials are required to prove the benefit of HCQ in patients with RA for the prevention of MACE, cerebral ischemia, and AMI.

Limitations

Several limitations in our study should be pointed out. We analyzed a large database containing information from electronic medical records, claiming clearing houses, and pharmacy claims and therefore could not verify the accuracy of reporting of diseases and medications. We could not account for severity of disease; we tried to mitigate this with subgroup analysis of patients taking other DMARDs and PSM. We could not account for medication duration, adherence, and dosage. Despite PSM, there might be other confounders that were not considered. Although most of the US healthcare data is included in the diamond network, it is possible that some patients had outcomes or medications reported in organizations not included in the database. In that case, the information could not have been analyzed.

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 537 KB)

Supplementary file2 (DOCX 44 KB)